Replies to post #141996 on Biotech Values

[DewDiligence]

From the AMLN article you posted:

Sanofi's current strategy is to extend the Lantus franchise by developing a titratable single-pen injection formulation of Lantus+Lyxumia, but movement into Phase III has been delayed several times and currently is expected to advance in 2013. That would put Sanofi behind Novartis’ Ideglira fixed-dose combination of Victoza and Degludec, for which data is likely to be published in July or August.

They meant Novo, not Novartis!